



Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Zang et al.

FILED: July 02, 2003

SERIAL NO.: 10/612,468

**FOR: T Cell Receptor CDR3 Sequence and Methods
for Detecting and Treating Rheumatoid Arthritis**

§
§
§
§
§
§
§

ART UNIT:

1644

EXAMINER:

Juedes, A.E.

DOCKET:

D6622

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT AND
CERTIFICATE OF MAILING UNDER 37 CFR 1.8**


Dear Sir:

In response to a Restriction Requirement, mailed March 09, 2006, for the above-referenced application, Applicants elect Group 4, claims 10-11, 13-14 and 42-44 drawn to an isolated peptide derived from a BV16 TCR, or an isolated peptide comprising SEQ ID NO: 4, SQD, SLL or SEQ ID NO: 5 and pharmaceutical compositions thereof, without traverse. Applicant further provisionally elects the species SEQ ID NO: 4, with traverse. Claims 10-11, 13-14 and 42-44 read on the elected species.

I certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date below and is addressed to MS Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: Aug 10, 2006
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
Tel: (713) 270-5391
Fax: (713) 270-5361
BADLER1@houston.rr.com


Benjamin Aaron Adler, Ph.D., J.D.
Registration No. 35,423
Counsel for Applicant